News & Media

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

   Press Release

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

   Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

New study setting the stage for non-opioid analgesic in post-surgical pain management

   Press Release

AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more

AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform

   Press Release

AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more

AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge

   Press Release

AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more

How AMT-143 could reduce the post-surgical need for opioids

   Press Release

In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation. Watch the animated explainer inside this article.Read more

AmacaThera featured in Innovate Toronto

   Media Coverage

AmacaThera’s drug development platform is featured in Innovate Toronto, an in-depth look at Toronto’s innovation ecosystem. The online compendium and coffee table book features over 300 start-up success stories, including Kepler, which aims to take the Internet into space, and Altus Assessments, which is using data and tech to bring the human side of healthcare education back into focus.
Read more

AmacaThera animation showcases company’s unique biotechnology

   Press Release

In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a one-minute animation that outlines its approach to drug development.Read more

AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute

   Press Release

adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.Read more

Top20 Amaca Thera FB

AmacaThera named CIX Top 20 Early company

   Press Release

Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021.Read more

CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly Shoichet

   Media Coverage

ICYMI: Thanks to CBC's Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.Read more

Out of the lab molly

Out of the lab, into the marketplace

   Media Coverage

Globe and Mail features AmacaThera’s Series A financingRead more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

416-360-2094
MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]